title: Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study.
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, Germany.|Centre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany.
authors.forename: Gesine B
authors.initials: GB
authors.lastname: Szurman
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, Germany.|Centre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany.
authors.forename: Kai
authors.initials: K
authors.lastname: Januschowski
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, Germany.|Centre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Szurman
authors.affiliation: University Eye Hospital, University of Goettingen, Goettingen, Germany.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Feltgen
authors.affiliation: Department of Neurology and Bernstein Center for Computational Neuroscience, Charité, Berlin, Germany.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Spitzer
authors.affiliation: Department of Ophthalmology, Hannover Medical School, Hannover, Germany.
authors.forename: Amelie
authors.initials: A
authors.lastname: Pielen
authors.affiliation: University Eye Hospital, University of Leipzig, Leipzig, Germany.
authors.forename: Matus
authors.initials: M
authors.lastname: Rehak
authors.affiliation: Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Spital
authors.affiliation: Eye Clinic Sulzbach, Knappschaftsklinikum Saar, Sulzbach, Germany.
authors.forename: Spyridon
authors.initials: S
authors.lastname: Dimopoulos
authors.affiliation: Department of Ophthalmology, Pallace Clinics, Aarau, Switzerland.
authors.forename: Carsten H
authors.initials: CH
authors.lastname: Meyer
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D015337:Multicenter Studies as Topic / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab